CLINICAL_TRIALS
trial_result
· 2013-05-06
Clinical Trial Update: Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome [Phase 2]
Summary
A Phase 2 safety, tolerability and efficacy study of STX209 (arbaclofen) in Fragile X syndrome has completed with results posted in 2013.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Seaside Therapeutics, Inc. | Conditions: Fragile X Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2013-05-06